Rasagiline: a review of its use in the management of Parkinson's disease
about
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor featuresTherapeutic neuroprotective agents for amyotrophic lateral sclerosisNew recombinant cyclohexylamine oxidase variants for deracemization of secondary amines by orthogonally assaying designed mutants with structurally diverse substrates.Zydis selegiline in the management of Parkinson's disease.Selegiline transdermal system: a novel treatment option for major depressive disorder.Safety of rasagiline for the treatment of Parkinson's disease.Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome.Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.Rasagiline and rapid symptomatic motor effect in Parkinson's disease: review of literature.An Overview of Analytical Methods for the Determination of Monoamine Oxidase Inhibitors in Pharmaceutical Formulations and Biological Fluids.Covalent Inhibition of HIV-1 Integrase by N-Succinimidyl Peptides.Role of rasagiline in treating Parkinson's disease: Effect on disease progression.Reversed-Phase UHPLC Enantiomeric Separation of Rasagiline Salts Using a Chiralpak® AGP Column.A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson's disease models.Cross-Dehydrogenative Coupling of Tertiary Amines and Terminal Alkynes Catalyzed by Copper Nanoparticles on Zeolite
P2860
Q24644555-0BD10744-842E-421C-8687-A404FED6A780Q27015029-9ED817C3-9F68-42E5-BAA7-52D26BE9B06FQ36006405-99BECD2B-1520-4698-ACBD-D460E88F7D47Q36968199-0EC69ADD-8661-4F02-B901-A65EDAE98507Q37519729-58F932C8-A8FB-4DB0-A0B9-C9387079087DQ37859776-D07C9DC3-6CCF-445D-82EA-4C979DBF94DEQ37996077-74177C79-4302-4EA5-95F1-3648F4B4FCC9Q38242390-52F526F3-78B7-45A9-8184-7EC413D6A20FQ38260834-7C70D6CA-F3D1-4C3E-8D49-1B53DD8037EAQ38497529-F9D91DC8-775E-4DFA-9393-9E951AD602C1Q38974856-FF541A03-4C37-416E-985F-F79E2D270EBBQ40688076-5CA6EE24-96DC-4A91-AAA6-E79743EFC945Q41527937-C6587110-7570-4BF5-ACAE-D4A2DC54BA4DQ42366792-B017DCF7-4ADB-4280-A28C-93370BD33844Q52766051-05527312-7E2B-412C-A5F5-BBD4FE10BF40Q57832582-8A0E0BEC-BCA7-4687-8E06-F2466D97E937
P2860
Rasagiline: a review of its use in the management of Parkinson's disease
description
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2007
@ast
im Januar 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 2007)
@en
vedecký článok (publikovaný 2007)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd in 2007)
@nl
наукова стаття, опублікована у 2007
@uk
مقالة علمية (نشرت عام 2007)
@ar
name
Rasagiline: a review of its use in the management of Parkinson's disease
@ast
Rasagiline: a review of its use in the management of Parkinson's disease
@en
Rasagiline: a review of its use in the management of Parkinson's disease
@nl
type
label
Rasagiline: a review of its use in the management of Parkinson's disease
@ast
Rasagiline: a review of its use in the management of Parkinson's disease
@en
Rasagiline: a review of its use in the management of Parkinson's disease
@nl
prefLabel
Rasagiline: a review of its use in the management of Parkinson's disease
@ast
Rasagiline: a review of its use in the management of Parkinson's disease
@en
Rasagiline: a review of its use in the management of Parkinson's disease
@nl
P2860
P3181
P1433
P1476
Rasagiline: a review of its use in the management of Parkinson's disease
@en
P2093
Vicki Oldfield
P2860
P304
P3181
P356
10.2165/00003495-200767120-00006
P407
P577
2007-01-01T00:00:00Z
P6179
1016330905